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anti-hyperlipidemia drugs, despite LDL-c levels above 160 mg/dL. Many reported 
themselves untreated for 3 years. These results revealed a potentially critical gap 
between health care checkup results and subject’s behavior to access medical treat-
ment, suggesting more effective interventions to modify behavior is required.
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Objectives: 1) Survey to evaluate the effectiveness of Drug Price Control Order 
(DPCO)2013: a health care policy devised by Government of India, and 2) To ana-
lyze the cost minimization benefits of the anti-hypertensive drugs falling under 
Drug Price Control Order (DPCO)2013 to the patients receiving palliative treat-
ment. MethOds: Three sets of structured questionnaires were designed which cap-
tured the patient’s gender, prescription trends for hypertensive patients in Mumbai, 
India. The survey through questionnaires, targeted 20 General Practioners, 75 Retail 
Pharmacies and 25 patients. Results: 1. Out of the total prescriptions received 
by Retail Pharmacies; Amlodipine accounted for 42%, Telmisartan: 27%, Atenolol: 
20% and Ramipril: 10%. The same trend was followed by the General Practioners. 
Amlodipine and Atenolol account for 63% of all prescriptions when considered 
together. These fall under Drug Price Control Order (DPCO)2013 and their selling 
price is Government capped and is therefore low. Telmisartan and Ramipril which 
do not fall under Drug Price Control Order (DPCO)2013 account for 37% when con-
sidered together. 2. Gender study of patient established the fact that more males 
(70%) are prone to hypertension than females(30%). 3. The average cost per dose of 
generics surveyed (Amlodipine, Atenolol) which fall under DPCO 2013 is 0.02USD 
(1.175INR) whereas that of generics (Telmisartan and Ramipril) which do not fall 
under DPCO 2013 is 0.1USD(6.3INR). cOnclusiOns: 1. Amlodipine and Atenolol 
which fall under Drug Price Control Order (DPCO) 2013 are majorly prescribed as 
compared to Telmisartan and Ramipril which do not fall under Drug Price Control 
Order (DPCO)2013. 2. The drugs which fall under DPCO 2013 are 5 times less expen-
sive than those that do not fall under DPCO 2013. Thus, the initiative taken by 
Government of India by devising this policy has made it economically viable for 
patients with palliative hypertension to meet their daily requirement of drugs.
MEntal HEaltH – Clinical outcomes studies
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Objectives: To estimate the effectiveness and adverse effect rate of five anti-
depression drugs: fluoxetine, venlafaxine, maprotiline, mirtazapine and bupro-
pion ; and to systematically review those common used new antidepression 
drugs’efficacy and safety in China. MethOds: we retrieve clinical research paper 
through Chinese Journal Full Text Database (1994-2014.2), Chinese Biomedical Literature 
Database (1978-2014.2), Chinese Technology Journal Full-text Database(1989-2014.2), 
Wanfang Data of Medical Information Mirror System (1997-2014.2), Digital Journal Full 
Text Database (1997-2014.2), PubMed (1966-2014.2), Cochrane Library (2014), EMBASE 
(1974-2014.2), ISI database(1974-2014.2). We screen these papers according to the 
inclusion and exclusion criteria and assess the quality of these included researches 
. Network Meta analysis method is used to combine the RCT results . WinBUGS 
and R software are used as instrument for statistical analysis to systematically 
assess OR values and quality rank of these five drugs. Results: 89 clinical tri-
als, 7007 patients with depression, 180 arms are totally included. Network Meta-
analysis showes that fluoxetine improves effectiveness more obviously than 
venlafaxine and mirtazapine. ORvenlafaxine-fluoxetine = 0.6741[95%CI:0.5313, 0.8307], 
ORfluoxetine - mirtazapine = 1.5887 [95%CI:1.2369, 2.0220], P< 0.05. In terms of adverse 
effects, maprotiline leads to the least adverse effects rate. ORbupropion-maprotiline 
= 8.6945[95%CI:2.1496,26.4462], ORmaprotiline-venlafaxine= 0.2086 [95%CI: 0.0627,0.4958], 
ORmaprotiline-fluoxetine = 0.2109[95%CI:0.0607, 0.5422], ORmaprotiline - mirtazapine = 0.2521 
[95%CI:0.0773, 0.6173], P< 0.05. Based on bayesian theory, network meta-analysis 
also ranks these five interventions. Results show that fluoxetine, bupropion and 
maprotiline have better effectiveness; but maprotiline, fluoxetine, mirtazapine have 
less adverse effects rate. cOnclusiOns: Fluoxetine, as a new antidepressant drug, 
has higher clinical efficiency and lower adverse effects rate. Although maprotiline 
has a high grade of recommendation, we have few researches integrated into the 
model, further prospective studies are needed for strong evidence to support analo-
gous research.
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Objectives: Minimum Clinically Important Difference (MCID) can aid to assess 
the quality of improvement in functioning assessed by the Global Assessment 
Functioning (GAF). This scale, ranging between 0 and 100, subjectively rates the 
social, occupational, and psychological functioning of adults. The objective of this 
study was to generate MCID for GAF, based on a longitudinal cohort of patients with 
schizophrenia. MethOds: Two methods exist to assess MCID in scales such as GAF: 
the anchor-based approach (comparison of the change in CDSS score and Clinical 
Global Impression (CGI) within- and between-patients), and the distribution-based 
approach (comparison between the change in PRO scores and some measure of 
variability, including standard error measurement approach, standard deviation 
approach and effect size). Both methods were implemented in a longitudinal cohort 
PCV55
assoCiation of DiEtary PattErns anD blooD PrEssurE in taiwanEsE 
fEMalEs
Ho C.P., Lee T.J.F.
Tzu Chi University, Hualien, Taiwan
Objectives: This study aimed to explore the relationship between the dietary pat-
terns and blood pressure (BP) in Taiwanese females. MethOds: Cross-sectional 
study by surveying 269 Taiwanese females, 40 years of age or older, was conducted, 
using structured questionnaires, and BP and physiological parameters measure-
ments. Descriptive statistics were performed for all measures as appropriate. To 
assess differences among the vegan, semi-vegetarian, and meat-eater groups by 
demographic, BP and health behavior data, Chi-Square test and Fisher’s exact test 
for categorical variables, or analysis of variance tests and independent t-test for 
continuous variables were performed. The relationship between BP and dietary 
patterns was assessed using a multiple linear regression (MLR) model. All data 
were analyzed using SPSS 20.0 statistical analysis software. Results: Among the 
total participants, 65 (24.2%), 105 (39.0%), and 99 (36.8%) were the vegan, semi-
vegetarian, and meat-eater groups. Significant difference was found among three 
groups according to age, race, educational, employment, stress and waist-hip ratio. 
Based on BP, the systolic blood pressure (SBP) and diastolic blood pressure (DBP) 
were significantly different among the three groups. When SBP and DBP were con-
sidered independently, waist-hip ratio was significantly different between the good 
and poor controls in both SBP and DBP. Therefore, BP was predicted as a function 
of the three groups considering for waist-hip ratio. The R2 for the MLR model was 
0.02, indicating that 2% of the variance in SBP and DBP were accounted for by the 
independent variables. The three groups were observed to be a significant predictor 
of SBP (β = 0.14, p= .02) and DBP (β = 0.15, p= .02). cOnclusiOns: The dietary pattern 
is a predictor for the SBP and DBP outcome in Taiwanese females.
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Objectives: A number of studies have examined the impacts of pay-for-perfor-
mance programs on quality of care, but little is known about long-term effects of 
these programs on the health care outcomes. This study aimed at examine the 
effects of the pay-for-performance program for type 2 diabetes patients on diabetes-
related complications under the National Health Insurance in Taiwan. MethOds: 
A longitudinal cohort study with 5-year follow-up was used to evaluate the effects 
of the pay-for-performance program on diabetes-related complications. Research 
materials came from claims files of the Longitudinal Health Insurance Database 
(LHID) 2005 released by the National Health Research Institute in Taiwan. Patients 
newly diagnosed as diabetes in 2004-2006 were included in the study. Patients joined 
the pay-for-performance program and received the comprehensive care over 12 
months during 2004 to 2010 were categorized as the case group. Patients never 
joined the pay-for-performance program during follow-up period were categorized 
as control group. Since patients who enrolled in the pay-for-performance program 
or not is not randomization, we applied the propensity score matching (PSM) to 
increase the comparatives between these two groups. The outcomes were the inci-
dences of cardiovascular diseases. Results: Patients in the case group experienced 
cardiovascular event significantly later than control group. The marginal hazard 
ratios of different propensity score method ranged from 0.60 to 0.63. Patients in the 
case group also had significant lower risks of heart failure, myocardial infarction 
and stroke between than patients in the control group. cOnclusiOns: The pay-
for-performance program may have reduced the incidence of cardiovascular events 
among patients newly diagnosed with diabetes who participated in the program 
for over 12 months.
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Objectives: To investigate the LDL-c levels and pharmaceutical interventions in 
Japanese subjects under real life settings based on longitudinal data from a Japanese 
health care checkup database developed by MinaCare Co. Ltd. MethOds: Data 
of those subjects with annual health checkup from 2010 to 2012 were extracted 
from MinaCare database (cutoff November 2013). From these data, 11830 subjects 
with 3 years of parameter values (LDL-c, etc.) were used to assess their longitudi-
nal changes and the self-reported use of medications. The reliability of MinaCare 
database has been evaluated in a separate investigation to be presented at ISPOR 
19th Annual International Meeting. The final report of this investigation will be 
based on the latest of the periodically updated database at reporting. Results: At 
baseline (2010), 11.9% (1410/11830) of the subjects reported LDL-c≥ 160 mg/dL (tar-
get level for low risk hyperlipidemia population). Despite these high LDL-c values, 
95.4% (1345/1410) of these subjects answered “untreated by anti-hyperlipidemia 
drug” (including one non-respondent). Among these 1345 subjects, 1257(93.5%) 
answered “untreated” again in 2011; and among these “untreated”, the proportions 
of subjects with LDL-c< 140 (diagnositic level for hyperlipidemia), 160< LDL-c≤ 180 
and LDL-c≥ 180 in 2011 were 13.5%(n= 170), 32.9%(n= 413) and 22.9%(n= 228), respec-
tively. In contrast, among those who answered “treated” in 2011, the proportion 
with LDL-c< 140 was dramatically higher (69.8%, n= 60).Additionally, among those 
who answered “untreated” in 2011, the proportion answering “untreated” in 2012 
(i.e. “untreated” in 3-consecutive years) was 94.1% (n= 1183); among these subjects, 
the proportions of subjects with LDL-c< 140, 160< LDL-c≤ 180 and LDL-c≥ 180 in 2012 
were 16.5%(n= 195), 29.8%(n= 352) and 25.0%(n= 296), respectively. cOnclusiOns: 
Our investigation showed that > 90% of subjects self-reported no treatment with 
